2025 ICD-10-CM Diagnosis Code T45.1X5A

Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter

ICD-10-CM Code:
T45.1X5A
ICD-10 Code for:
Adverse effect of antineoplastic and immunosup drugs, init
Is Billable?
Yes - Valid for Submission
Chronic Condition Indicator: [1]
Not chronic
Code Navigator:

T45.1X5A is a billable diagnosis code used to specify a medical diagnosis of adverse effect of antineoplastic and immunosuppressive drugs, initial encounter. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2024 through September 30, 2025.

This code describes a circumstance which influences the patient's health status but not a current illness or injury. The code is unacceptable as a principal diagnosis.

T45.1X5A is an initial encounter code, includes a 7th character and should be used while the patient is receiving active treatment for a condition like adverse effect of antineoplastic and immunosuppressive drugs. According to ICD-10-CM Guidelines an "initial encounter" doesn't necessarily means "initial visit". The 7th character should be used when the patient is undergoing active treatment regardless if new or different providers saw the patient over the course of a treatment. The appropriate 7th character codes should also be used even if the patient delayed seeking treatment for a condition.

Code Classification

  • Injury, poisoning and certain other consequences of external causes
    S00–T88
    • Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
      T36-T50
      • Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified
        T45

Approximate Synonyms

The following list of clinical terms are approximate synonyms, alternative descriptions, or common phrases that might be used by patients, healthcare providers, or medical coders to describe the same condition. These synonyms and related diagnosis terms are often used when searching for an ICD-10 code, especially when the exact medical terminology is unclear. Whether you're looking for lay terms, similar diagnosis names, or common language alternatives, this list can help guide you to the correct ICD-10 classification.

  • Accelerated rheumatoid nodulosis
  • Accelerated rheumatoid nodulosis caused by methotrexate
  • Aclarubicin adverse reaction
  • Acquired pancytopenia
  • Acral erythema due to cytotoxic therapy
  • Acute promyelocytic leukemia, FAB M3
  • Adverse reaction to antineoplastic antibiotics
  • Adverse reaction to dimethyl sulfoxide and/or idoxuridine
  • Adverse reaction to rituximab administered by infusion
  • Adverse reaction to sarilumab
  • Adverse reaction to trastuzumab administered by infusion
  • Adverse reaction to triazene
  • Agranulocytosis
  • Agranulocytosis due to and following administration of antineoplastic agent
  • Aldesleukin adverse reaction
  • Alkylating drug adverse reaction
  • Amifostine adverse reaction
  • Amsacrine adverse reaction
  • Anemia caused by antineoplastic agent
  • Antimetabolite adverse reaction
  • Antineoplastic adverse reaction
  • Aplastic anemia caused by antineoplastic agent
  • Aplastic anemia due to drugs
  • Azathioprine adverse reaction
  • Azoospermia caused by chemotherapy
  • Bleomycin adverse reaction
  • Busulfan adverse reaction
  • Carboplatin adverse reaction
  • Cardiomyopathy caused by drug
  • Carmustine adverse reaction
  • Cellular atypia caused by antineoplastic agent
  • Chlorambucil adverse reaction
  • Chlormethine adverse reaction
  • Chronic cyclosporin A nephrotoxicity
  • Chronic drug-induced renal disease
  • Chronic drug-induced renal disease
  • Chronic drug-induced renal disease
  • Chronic painful polyneuropathy
  • Chronic painful polyneuropathy following chemotherapy
  • Chronic peripheral neuropathic pain
  • Cirrhosis of liver caused by methotrexate
  • Cisplatin adverse reaction
  • Cis-platinum nephropathy
  • Complication of chemotherapy
  • Crisantaspase adverse reaction
  • Cyclophosphamide adverse reaction
  • Cyclosporin adverse reaction
  • Cytarabine adverse reaction
  • Cytotoxic antibiotic adverse reaction
  • Dacarbazine adverse reaction
  • Dactinomycin adverse reaction
  • Dermatosis caused by immunosuppressant
  • Dermatosis due to cytotoxic therapy
  • Differentiation syndrome due to and following chemotherapy co-occurrent with acute promyelocytic leukemia
  • Dilated cardiomyopathy caused by anthracycline
  • Dilated cardiomyopathy caused by drug
  • Dimethyl sulfoxide adverse reaction
  • Disorder of skin caused by epidermal growth factor receptor inhibitor
  • Doxorubicin adverse reaction
  • Drug-induced cirrhosis of liver
  • Drug-induced immunodeficiency
  • Drug-induced immunodeficiency
  • Drug-induced tubulointerstitial nephritis
  • Epirubicin adverse reaction
  • Esophagitis due to chemotherapy
  • Estramustine adverse reaction
  • Ethoglucid adverse reaction
  • Etoposide adverse reaction
  • Fatigue due to chemotherapy
  • Fludarabine adverse reaction
  • Fluorouracil adverse reaction
  • Gonad regulating hormone adverse reaction
  • Gonad regulating hormone adverse reaction
  • Gonad regulating hormone adverse reaction
  • Goserelin adverse reaction
  • Growing teratoma syndrome
  • Heart failure following administration of antineoplastic agent
  • Hematologic complication of procedure
  • Hematologic complication of procedure
  • Hydroxycarbamide adverse reaction
  • Iatrogenic immunodeficiency-associated lymphoproliferative disorder
  • Idarubicin adverse reaction
  • Ifosfamide adverse reaction
  • Immunodeficiency caused by long term therapeutic use of drug
  • Immunodeficiency caused by long term therapeutic use of immunosuppressant
  • Immunodeficiency secondary to chemotherapy
  • Immunosuppressant adverse reaction
  • Inflammation of mucous membrane due to and following chemotherapy
  • Leuprorelin adverse reaction
  • Lomustine adverse reaction
  • Lymphoproliferative disorder caused by methotrexate
  • Malignant neoplasm after immunosuppressive therapy
  • Melphalan adverse reaction
  • Mercaptopurine adverse reaction
  • Methotrexate adverse reaction
  • Methotrexate poisoning
  • Methotrexate skin ulceration
  • Methyl CCNU nephropathy
  • Mitobronitol adverse reaction
  • Mitomycin adverse reaction
  • Mitoxantrone adverse reaction
  • Myelopathy post intrathecal injection of chemotherapeutic agent
  • Myelosuppression
  • Myelosuppression due to chemotherapy
  • Nephritis caused by drug
  • Nephropathy induced by cyclosporine
  • Nephropathy induced by tacrolimus
  • Neurological pain disorder
  • Neurotoxicity caused by L-asparaginase
  • Neurotoxicity caused by methotrexate
  • Neurotoxicity caused by procarbazine
  • Neurotoxicity caused by vinblastine
  • Neurotoxicity caused by vincristine
  • Nitrogen mustard derivative adverse reaction
  • Nitrosurea adverse reaction
  • Paclitaxel adverse reaction
  • Palmar erythema
  • Pancytopenia caused by immunosuppressant
  • Pancytopenia caused by medication
  • Pancytopenia caused by medication
  • Pentostatin adverse reaction
  • Peripheral neuropathic pain
  • Peripheral neuropathy due to and following antineoplastic therapy
  • Plicamycin adverse reaction
  • Poisoning by L-asparaginase
  • Post-immunosuppression viral warts
  • Procarbazine adverse reaction
  • Procarbazine poisoning
  • Razoxane adverse reaction
  • Retinoid adverse reaction
  • Ruxolitinib withdrawal
  • Secondary aplastic anemia
  • Stomatitis due to cytotoxic therapy
  • Stomatitis medicamentosa
  • Stomatitis medicamentosa
  • Terpenes adverse reaction
  • Terpenes adverse reaction
  • Therapy related acute myeloid leukemia due to and following administration of antineoplastic agent
  • Therapy-related myelodysplastic syndrome
  • Thioguanine adverse reaction
  • Thiotepa adverse reaction
  • Thrombophilia due to antineoplastic agent therapy
  • Toxic cardiomyopathy
  • Toxic dilated cardiomyopathy
  • Treosulfan adverse reaction
  • Triptorelin adverse reaction
  • Ulcerative inflammation of oral mucous membrane due to and following administration of antineoplastic agent
  • Ulcerative stomatitis
  • Vinblastine adverse reaction
  • Vinblastine poisoning
  • Vinca alkaloid adverse reaction
  • Vincristine adverse reaction
  • Vincristine poisoning
  • Vindesine adverse reaction
  • Warts in immune-deficient state

Clinical Classification

Clinical Classifications group individual ICD-10-CM diagnosis codes into broader, clinically meaningful categories. These categories help simplify complex data by organizing related conditions under common clinical themes.

They are especially useful for data analysis, reporting, and clinical decision-making. Even when diagnosis codes differ, similar conditions can be grouped together based on their clinical relevance. Each category is assigned a unique CCSR code that represents a specific clinical concept, often tied to a body system or medical specialty.

Adverse effects of drugs and medicaments, initial encounter

CCSR Code: INJ028

Inpatient Default: X - Not applicable.

Outpatient Default: Y - Yes, default outpatient assignment for principal diagnosis or first-listed diagnosis.

Clinical Information

  • Agranulocytosis

    a decrease in the number of granulocytes; (basophils; eosinophils; and neutrophils).
  • Feline Panleukopenia

    a highly contagious dna virus infection of the cat family, characterized by fever, enteritis and bone marrow changes. it is also called feline ataxia, feline agranulocytosis, feline infectious enteritis, cat fever, cat plague, and show fever. it is caused by feline panleukopenia virus or the closely related mink enteritis virus or canine parvovirus.
  • Agranulocytosis

    a marked decrease in the number of mature granulocytes (most often neutrophils) in the peripheral blood.
  • Chemotherapy Related Agranulocytosis|Chemotherapy-Related Agranulocytosis

    agranulocytosis that occurs with chemotherapy.
  • Congenital Neutropenia|congenital neutropenia|genetic infantile agranulocytosis|infantile genetic agranulocytosis

    a rare congenital disorder characterized by mild or severe reduction of neutrophils in the peripheral blood and recurrent infantile infections.
  • Cyclic Neutropenia|CH|CN|Cyclic Agranulocytosis|Cyclic Hematopoiesis|Cyclic Hematopoiesis|Dysplasia, Myelocytic Periodic|Periodic Neutropenia|cyclic neutropenia|periodic neutropenia

    a hematologic disorder caused by a mutation in the elane (ela2) gene; clinical manifestations include recurrent neutropenia with resultant susceptibility to infection leading to fever.
  • Tumor Protein 63|CUSP|Chronic Ulcerative Stomatitis Protein|Keratinocyte Transcription Factor KET|TP63|Transformation-Related Protein 63|Tumor Protein p73-Like|p40|p51|p63|p73L

    tumor protein 63 (680 aa, ~77 kda) is encoded by the human tp63 gene. this protein plays a role in the mediation of both transcription and limb morphogenesis.
  • Ulcerative Stomatitis

    inflammation of the mouth mucosa associated with the presence of ulcers.

Coding Guidelines

When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified (T45). Use the following options for the aplicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Replaced Code

This code was replaced in the 2025 ICD-10-CM code set with the code(s) listed below. The National Center for Health Statistics (NCHS) has published an update to the ICD-10-CM diagnosis codes which became effective October 1, 2024. This code was replaced for the FY 2025 (October 1, 2024 - September 30, 2025).


  • T45.AX5A - Advrs effect of immune chkpt inhibtr/immunostim drugs, init

Code Edits

The Medicare Code Editor (MCE) detects errors and inconsistencies in ICD-10-CM diagnosis coding that can affect Medicare claim validity. These Medicare code edits help medical coders and billing professionals determine when a diagnosis code is not appropriate as a principal diagnosis, does not meet coverage criteria. Use this list to verify whether a code is valid for Medicare billing and to avoid claim rejections or denials due to diagnosis coding issues.

Unacceptable principal diagnosis

There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Convert T45.1X5A to ICD-9-CM

Below are the ICD-9 codes that most closely match this ICD-10 code, based on the General Equivalence Mappings (GEMs). This ICD-10 to ICD-9 crosswalk tool is helpful for coders who need to reference legacy diagnosis codes for audits, historical claims, or approximate code comparisons.

Adv eff med/biol NEC/NOS

ICD-9-CM: 995.29

Approximate Flag - The approximate mapping means this ICD-10 code does not have an exact ICD-9 equivalent. The matched code is the closest available option, but it may not fully capture the original diagnosis or clinical intent.

Adv eff antineoplastic

ICD-9-CM: E933.1

Approximate Flag - The approximate mapping means this ICD-10 code does not have an exact ICD-9 equivalent. The matched code is the closest available option, but it may not fully capture the original diagnosis or clinical intent.

Table of Drugs and Chemicals

The parent code T45.1X5 of the current diagnosis code is referenced in the Table of Drugs and Chemicals, this table contains a classification of drugs, industrial solvents, corrosive gases, noxious plants, pesticides, and other toxic agents.

According to ICD-10-CM coding guidelines it is advised to do not code directly from the Table of Drugs and Chemicals, instead always refer back to the Tabular List when doing the initial coding. Each substance in the table is assigned a code according to the poisoning classification and external causes of adverse effects. It is important to use as many codes as necessary to specify all reported drugs, medicinal or chemical substances. If the same diagnosis code describes the causative agent for more than one adverse reaction, poisoning, toxic effect or underdosing, utilize the code only once.

Substance Poisoning
Accidental
(unintentional)
Poisoning
Accidental
(self-harm)
Poisoning
Assault
Poisoning
Undetermined
Adverse
effect
Underdosing
AclarubicinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Actinomycin CT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Actinomycin DT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AdriamycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Alkylating drug NECT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Alkylating drug NEC
  »antimyeloproliferative
T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Alkylating drug NEC
  »lymphatic
T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AltretamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AmethopterinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AminoglutethimideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Aminopterin sodiumT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AmsacrineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AnthramycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Anticancer agents NECT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AntimetaboliteT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antimitotic agentT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antineoplastic NECT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antineoplastic NEC
  »alkaloidal
T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antineoplastic NEC
  »antibiotics
T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antineoplastic NEC
  »combination
T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antineoplastic NEC
  »combination
    »estrogen
T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antineoplastic NEC
  »steroid
T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Ara-CT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AsparaginaseT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AzacitidineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AzaribineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AzaserineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AzatepaT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AzathioprineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
BCNUT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
BenzcarbimineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
BleomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
BroxuridineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Busulfan, busulphanT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CactinomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Cancer chemotherapy drug regimenT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CarboplatinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CarboquoneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CarmofurT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CarmustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ChlorambucilT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ChlorhexamideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ChlormethineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ChloropurineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Chromomycin A3T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CiclosporinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CisplatinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ColaspaseT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Corynebacterium parvumT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CycloleucinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CyclophosphamideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CyclosporinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CytarabineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Cytosine arabinosideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CytoxanT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DacarbazineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DactinomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DaunomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DaunorubicinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DemecolcineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
2-Deoxy-5-fluorouridineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
5-Deoxy-5-fluorouridineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DibromodulcitolT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DibromomannitolT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DoxifluridineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DoxorubicinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DTICT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Elliptinium acetateT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
EnocitabineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
EpirubicinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
EstramustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
EtoglucidT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
EtoposideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
FAC (fluorouracil + doxorubicin + cyclophosphamide)T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
FloxuridineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
FluorodeoxyuridineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
FluorouracilT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
FtorafurT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
GoldT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Gold
  »colloidal (l98Au)
T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Gold
  »salts
T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
GoserelinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
HexamethylmelamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
HydroxycarbamideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
HydroxyureaT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
IdarubicinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
IfosfamideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Imidazole-4-carboxamideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Immunosuppressive drugT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
InproquoneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
IproplatinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
IsophosphamideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
LeukeranT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
LomustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
LonidamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
M-AMSAT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MannomustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MatulaneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MechlorethamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MelphalanT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MercaptopurineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MethotrexateT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MetoprineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MithramycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MitobronitolT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MitoguazoneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MitolactolT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MitomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MitopodozideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MitotaneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MitoxantroneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MopidamolT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MOPP (mechloreth-amine + vincristine + prednisone + procarba-zine)T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Muromonab-CD3T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
M-vacT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MyelobromalT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MyleranT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
NimustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
OlivomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
OncovinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ParoxypropioneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PentostatinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PeplomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Phenylalanine mustardT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PipobromanT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PirarubicinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PlicamycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PorfiromycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PrednimustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ProcarbazineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PteroyltriglutamateT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Purine analogue (antineoplastic)T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PurinetholT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Pyrimidine antagonistT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
RazoxaneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
RubidomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
RufocromomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
SarcolysinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
SarkomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
SemustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
StreptozocinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
StreptozotocinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TauromustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TegafurT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TEMT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TeniposideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TEPAT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ThalidomideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ThioguanineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ThiotepaT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TioguanineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TreosulfanT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TretamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TriaziquoneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TrichlormethineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TrichlorotriethylamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TriethanomelamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TriethylenemelamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TriethylenephosphoramideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TriethylenethiophosphoramideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TrimetrexateT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TrimustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TrofosfamideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Uracil mustardT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
UramustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
UrethaneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
VinblastineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
VincamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
VincristineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
VindesineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Vinorelbine tartrateT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ZinostatinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ZorubicinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6

Patient Education


Drug Reactions

Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.

What is a drug interaction?

A drug interaction is a change in the way a drug acts in the body when taken with certain other drugs, foods, or supplements or when taken while you have certain medical conditions. Examples include:

  • Two drugs, such as aspirin and blood thinners
  • Drugs and food, such as statins and grapefruit
  • Drugs and supplements, such as gingko and blood thinners
  • Drugs and medical conditions, such as aspirin and peptic ulcers

Interactions could cause a drug to be more or less effective, cause side effects, or change the way one or both drugs work.

What are side effects?

Side effects are unwanted, usually unpleasant, effects caused by medicines. Most are mild, such as a stomachache, dry mouth, or drowsiness, and go away after you stop taking the medicine. Others can be more serious. Sometimes a drug can interact with a disease that you have and cause a side effect. For example, if you have a heart condition, certain decongestants can cause you to have a rapid heartbeat.

What are drug allergies?

Drug allergies are another type of reaction. They can range from mild to life-threatening. Skin reactions, such as hives and rashes, are the most common type. Anaphylaxis, a serious allergic reaction, is less common.

How can I stay safe when taking medicines?

When you start a new prescription or over-the-counter medicine, make sure you understand how to take it correctly. Know which other medicines, foods, and supplements you need to avoid. Always talk to your health care provider or pharmacist if you have questions about your medicines.


[Learn More in MedlinePlus]

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.